Literature DB >> 30561672

PREVAIL I Cluster Vaccination Study With rVSVΔG-ZEBOV-GP as Part of a Public Health Response in Liberia.

Fatorma K Bolay1, Greg Grandits2, H Clifford Lane3, Stephen B Kennedy4, Melvin P Johnson5, Mosoka P Fallah1, Barthalomew Wilson5, Wissedi S Njoh6, Laura A McNay3, Lisa E Hensley3, Elizabeth S Higgs3.   

Abstract

OBJECTIVE: In November 2015, a 15-year-old boy received a diagnosis of Ebola virus disease (EVD) at the John F. Kennedy Medical Center in Monrovia, Liberia. Two additional family members received a diagnosis of EVD. The protocol for a phase 2 placebo-controlled trial of 2 Ebola vaccines was amended and approved; in 4 days, a single-arm cluster vaccination trial using the Merck rVSVΔG-ZEBOV-GP vaccine was initiated. Here, we evaluate the safety and immunogenicity of the vaccine and discuss challenges for its implementation in a small Ebola outbreak.
METHOD: We conducted a ring vaccination study among contacts and contacts of close contacts of EVD cases a in Monrovia. Participants were evaluated 1 and 6 months after vaccination.
RESULTS: Among 650 close contacts and contacts of close contacts of EVD cases, 210 (32%) consented and were vaccinated with rVSVΔG-ZEBOV-GP. Of those vaccinated, 189 (90%) attended the month 1 follow-up visit; 166 (79%) attended the month 6 visit. No serious adverse events were reported. Among 88 participants without an elevated antibody level at baseline, 77.3% (95% confidence interval, 68.5-86.1) had an antibody response at 1 month.
CONCLUSIONS: The Merck rVSVΔG-ZEBOV-GP vaccine appeared to be safe and immunogenic among the vaccinated individuals. However, fewer than one third of eligible individuals consented to vaccination. These data may help guide implementation decisions for of cluster vaccination programs in an Ebola cluster outbreak response situation. Published by Oxford University Press for the Infectious Diseases Society of America 2018.

Entities:  

Keywords:  Ebola virus; Ebola virus disease; Liberia; PREVAIL; cluster vaccination; outbreak response; rVSVΔG-ZEBOV-GP vaccine; ring vaccination; vaccine

Mesh：

Substances：

Year:  2019        PMID： 30561672      PMCID： PMC6562162          DOI： 10.1093/infdis/jiy698

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  10 in total

1.  A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Authors:  Jason A Regules; John H Beigel; Kristopher M Paolino; Jocelyn Voell; Amy R Castellano; Zonghui Hu; Paula Muñoz; James E Moon; Richard C Ruck; Jason W Bennett; Patrick S Twomey; Ramiro L Gutiérrez; Shon A Remich; Holly R Hack; Meagan L Wisniewski; Matthew D Josleyn; Steven A Kwilas; Nicole Van Deusen; Olivier Tshiani Mbaya; Yan Zhou; Daphne A Stanley; Wang Jing; Kirsten S Smith; Meng Shi; Julie E Ledgerwood; Barney S Graham; Nancy J Sullivan; Linda L Jagodzinski; Sheila A Peel; Judie B Alimonti; Jay W Hooper; Peter M Silvera; Brian K Martin; Thomas P Monath; W Jay Ramsey; Charles J Link; H Clifford Lane; Nelson L Michael; Richard T Davey; Stephen J Thomas
Journal:  N Engl J Med       Date:  2015-04-01       Impact factor: 91.245

Review 2.  Defining research when it comes to public health.

Authors:  D E Snider; D F Stroup
Journal:  Public Health Rep       Date:  1997 Jan-Feb       Impact factor: 2.792

3.  The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.

Authors:  Angela Huttner; Julie-Anne Dayer; Sabine Yerly; Christophe Combescure; Floriane Auderset; Jules Desmeules; Markus Eickmann; Axel Finckh; Ana Rita Goncalves; Jay W Hooper; Gürkan Kaya; Verena Krähling; Steve Kwilas; Barbara Lemaître; Alain Matthey; Peter Silvera; Stephan Becker; Patricia E Fast; Vasee Moorthy; Marie Paule Kieny; Laurent Kaiser; Claire-Anne Siegrist
Journal:  Lancet Infect Dis       Date:  2015-08-04       Impact factor: 25.071

4.  Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

Authors:  Ana Maria Henao-Restrepo; Ira M Longini; Matthias Egger; Natalie E Dean; W John Edmunds; Anton Camacho; Miles W Carroll; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Stefanie Hossmann; Mandy Kader Kondé; Souleymane Kone; Eeva Kuisma; Myron M Levine; Sema Mandal; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; Conall H Watson; Sakoba Kéïta; Marie Paule Kieny; John-Arne Røttingen
Journal:  Lancet       Date:  2015-08-03       Impact factor: 79.321

5.  Conducting clinical trials in outbreak settings: Points to consider.

Authors:  H Clifford Lane; Hilary D Marston; Anthony S Fauci
Journal:  Clin Trials       Date:  2016-01-14       Impact factor: 2.486

6.  Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.

Authors:  Stephen B Kennedy; Fatorma Bolay; Mark Kieh; Greg Grandits; Moses Badio; Ripley Ballou; Risa Eckes; Mark Feinberg; Dean Follmann; Birgit Grund; Swati Gupta; Lisa Hensley; Elizabeth Higgs; Krisztina Janosko; Melvin Johnson; Francis Kateh; James Logue; Jonathan Marchand; Thomas Monath; Martha Nason; Tolbert Nyenswah; François Roman; Eric Stavale; Julian Wolfson; James D Neaton; H Clifford Lane
Journal:  N Engl J Med       Date:  2017-10-12       Impact factor: 91.245

7.  Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.

Authors:  Olga De Santis; Régine Audran; Emilie Pothin; Loane Warpelin-Decrausaz; Laure Vallotton; Grégoire Wuerzner; Camille Cochet; Daniel Estoppey; Viviane Steiner-Monard; Sophie Lonchampt; Anne-Christine Thierry; Carole Mayor; Robert T Bailer; Olivier Tshiani Mbaya; Yan Zhou; Aurélie Ploquin; Nancy J Sullivan; Barney S Graham; François Roman; Iris De Ryck; W Ripley Ballou; Marie Paule Kieny; Vasee Moorthy; François Spertini; Blaise Genton
Journal:  Lancet Infect Dis       Date:  2015-12-23       Impact factor: 25.071

8.  Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).

Authors:  Ana Maria Henao-Restrepo; Anton Camacho; Ira M Longini; Conall H Watson; W John Edmunds; Matthias Egger; Miles W Carroll; Natalie E Dean; Ibrahima Diatta; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Pierre-Stéphane Gsell; Stefanie Hossmann; Sara Viksmoen Watle; Mandy Kader Kondé; Sakoba Kéïta; Souleymane Kone; Eewa Kuisma; Myron M Levine; Sema Mandal; Thomas Mauget; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; John-Arne Røttingen; Marie-Paule Kieny
Journal:  Lancet       Date:  2016-12-23       Impact factor: 79.321

9.  Conducting research in disease outbreaks.

Authors:  Ruth Macklin; Ethan Cowan
Journal:  PLoS Negl Trop Dis       Date:  2009-04-28

10.  Persistence of Ebola virus after the end of widespread transmission in Liberia: an outbreak report.

Authors:  Emily Kainne Dokubo; Annika Wendland; Suzanne E Mate; Jason T Ladner; Esther L Hamblion; Philomena Raftery; David J Blackley; A Scott Laney; Nuha Mahmoud; Gloria Wayne-Davies; Lisa Hensley; Eric Stavale; Lawrence Fakoli; Christopher Gregory; Tai-Ho Chen; Augustine Koryon; Denise Roth Allen; Jennifer Mann; Andrew Hickey; John Saindon; Mehboob Badini; April Baller; Peter Clement; Fatorma Bolay; Yatta Wapoe; Michael R Wiley; James Logue; Bonnie Dighero-Kemp; Elizabeth Higgs; Alex Gasasira; Desmond E Williams; Bernice Dahn; Francis Kateh; Tolbert Nyenswah; Gustavo Palacios; Mosoka P Fallah
Journal:  Lancet Infect Dis       Date:  2018-07-23       Impact factor: 25.071
  10 in total
  5 in total

1.  Effect of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Vaccination on Ebola Virus Disease Illness and Death, Democratic Republic of the Congo.

Authors:  Neil Rupani; Mbong Eta Ngole; J Austin Lee; Adam R Aluisio; Monique Gainey; Shiromi M Perera; Lina Kashibura Ntamwinja; Ruffin Mbusa Matafali; Rigo Fraterne Muhayangabo; Fiston Nganga Makoyi; Razia Laghari; Adam C Levine; Alexis S Kearney
Journal:  Emerg Infect Dis       Date:  2022-06       Impact factor: 16.126

2.  Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease.

Authors:  Placide Mbala-Kingebeni; Catherine Pratt; Mbusa Mutafali-Ruffin; Matthias G Pauthner; Faustin Bile; Antoine Nkuba-Ndaye; Allison Black; Eddy Kinganda-Lusamaki; Martin Faye; Amuri Aziza; Moussa M Diagne; Daniel Mukadi; Bailey White; James Hadfield; Karthik Gangavarapu; Nella Bisento; Donatien Kazadi; Bibiche Nsunda; Marceline Akonga; Olivier Tshiani; John Misasi; Aurelie Ploquin; Victor Epaso; Emilia Sana-Paka; Yannick Tutu Tshia N'kasar; Fabrice Mambu; Francois Edidi; Meris Matondo; Junior Bula Bula; Boubacar Diallo; Mory Keita; Marie R D Belizaire; Ibrahima S Fall; Abdoulaye Yam; Sabue Mulangu; Anne W Rimion; Elias Salfati; Ali Torkamani; Marc A Suchard; Ian Crozier; Lisa Hensley; Andrew Rambaut; Ousmane Faye; Amadou Sall; Nancy J Sullivan; Trevor Bedford; Kristian G Andersen; Michael R Wiley; Steve Ahuka-Mundeke; Jean-Jacques Muyembe Tamfum
Journal:  N Engl J Med       Date:  2021-04-01       Impact factor: 91.245

Review 3.  Development of Pandemic Vaccines: ERVEBO Case Study.

Authors:  Jayanthi Wolf; Risat Jannat; Sheri Dubey; Sean Troth; Matthew T Onorato; Beth-Ann Coller; Mary E Hanson; Jakub K Simon
Journal:  Vaccines (Basel)       Date:  2021-02-25

4.  Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report.

Authors:  Chris Davis; Tom Tipton; Suleman Sabir; Celia Aitken; Susan Bennett; Stephan Becker; Tom Evans; Sarah Katharina Fehling; Rory Gunson; Yper Hall; Celia Jackson; Ingolfur Johanssen; Marie Paule Kieny; Jim Mcmenamin; Elizabeth Spence; Thomas Strecker; Catie Sykes; Kate Templeton; Fiona Thorburn; Erica Peters; Ana Maria Henao Restrepo; Beth White; Maria Zambon; Miles W Carroll; Emma C Thomson
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 9.079

5.  Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo.

Authors:  Nicole A Hoff; Anna Bratcher; J Daniel Kelly; Kamy Musene; Jean Paul Kompany; Michel Kabamba; Placide Mbala-Kingebeni; Bonnie Dighero-Kemp; Gregory Kocher; Elizabeth Elliott; Cavan Reilly; Megan Halbrook; Benoit Ilunga Kebela; Adva Gadoth; Guillaume Ngoie Mwamba; Merly Tambu; David R McIlwain; Patrick Mukadi; Lisa E Hensley; Steve Ahuka-Mundeke; George W Rutherford; Jean Jacques Muyembe-Tamfum; Anne W Rimoin
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-08       Impact factor: 12.779
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.